Exploring US High Growth Tech Stocks for Potential Expansion
AI Sentiment
Highly Positive
10/10
as of 12-30-2025 11:38am EST
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | GERMANTOWN |
| Market Cap: | 1.5B | IPO Year: | N/A |
| Target Price: | $7.67 | AVG Volume (30 days): | 5.0M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.76 - $5.22 | Next Earning Date: | 11-13-2025 |
| Revenue: | $6,309,000 | Revenue Growth: | 59.20% |
| Revenue Growth (this year): | 342.78% | Revenue Growth (next year): | 478.46% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Director, 10% Owner
Avg Cost/Share
$4.18
Shares
1,900,036
Total Value
$7,942,150.48
Owned After
4,598,044
Director
Avg Cost/Share
$3.63
Shares
235,467
Total Value
$855,899.00
Owned After
110,603
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| KIRK RANDAL J | PGEN | Director, 10% Owner | Dec 22, 2025 | Sell | $4.18 | 1,900,036 | $7,942,150.48 | 4,598,044 | |
| KINDLER JEFFREY B | PGEN | Director | Dec 12, 2025 | Sell | $3.63 | 235,467 | $855,899.00 | 110,603 |
PGEN Breaking Stock News: Dive into PGEN Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
10/10
AI Sentiment
Neutral
4/10
See how PGEN stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "PGEN Precigen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.